
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. has demonstrated notable growth in its reimbursement pipeline, increasing from 1,389 units in Q4 to 1,611 units in Q1, indicating a positive trend in market demand for its myoelectric orthosis products. The company's strategic focus on redirecting growth towards the large Medicare market is expected to bolster revenues, particularly as orthotics and prosthetics providers account for approximately 22% of projected revenue in 2024. Furthermore, a recent favorable ruling from the Centers for Medicare & Medicaid Services (CMS) to include MyoPro in Medicare Part B benefits significantly expands the company's addressable market, enhancing its financial outlook.
Bears say
Myomo Inc. has significantly reduced its revenue guidance for 2025 to $40-42 million, a decrease from the previous forecast of $50-53 million, indicating a declining outlook for the company’s financial performance. Furthermore, the company is experiencing challenges with its marketing efforts and pipeline quality, which have adversely impacted lead quality and conversion rates, suggesting difficulties in future customer acquisition. Additionally, the authorized insurance backlog has decreased to 230, down from 249 in Q1 and 272 in Q4, indicating a downward trend in demand for Myomo's products and potential cash flow concerns.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares